<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01572545</url>
  </required_header>
  <id_info>
    <org_study_id>PolyzosAnastasilakis</org_study_id>
    <nct_id>NCT01572545</nct_id>
  </id_info>
  <brief_title>Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin of Postmenopausal Women With Low Bone Mass</brief_title>
  <acronym>DenoZol</acronym>
  <official_title>Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin Levels of Postmenopausal Women With Low Bone Mass: A Multicenter, Randomized, Head-to-head Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>424 General Military Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>251 Hellenic Air Force &amp; VA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the study is the comparative effect of zolendronic acid versus denosumab
      on serum sclerostin levels in postmenopausal women with low bone mass.

      Secondary aims are their comparative effect on serum dickkopf-1, osteoprotegerin, receptor
      activator of nuclear factor kappaB ligand (RANKL) and bone turnover markers (procollagen type
      I N-terminal peptide [PINP] and C-terminal cross-linking telopeptide of type I collagen
      [CTX]).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoporosis is the most common bone disease, caused by a relatively increased rate of bone
      resorption by the osteoclasts that exceeds the rate of bone formation by the osteoblasts,
      resulting in net loss of bone mass. To-date, antiresorptive agents, which inhibit osteoclast
      activity and induce their apoptosis, are considered as the cornerstone of osteoporosis
      prevention and treatment.

      Bisphosphonates currently represent the first line antiresorptive agents for the management
      of postmenopausal osteoporosis. Zoledronic acid is considered to-date the most potent
      bisphosphonate. A once-yearly infusion of intravenous zoledronic acid decreases bone
      turnover, improves bone density and decreases the vertebral and non-vertebral fracture risk.

      Most recently, denosumab (AMG-162) has been launched for the treatment of postmenopausal
      osteoporosis. Denosumab, a fully human monoclonal IgG2 antibody against human RANKL,
      specifically binds and neutralizes the receptor activator of nuclear factor kappaB ligand
      (RANKL) in order to decrease bone resorption and subsequent bone loss. Subcutaneous
      administration of denosumab every six months decreases bone turnover markers, increases bone
      mineral density and reduces the vertebral and non-vertebral fracture risk.

      The role of sclerostin in bone metabolism is emerging. Sclerostin is the secreted expression
      of the SOST gene. In adult human bone, sclerostin is expressed only by osteocytes and
      inhibits bone formation by osteoblasts. It has been proposed that sclerostin expression by
      newly embedded osteocytes at the onset of osteoid mineralization may serve as a negative
      feedback signal on osteoblasts to prevent overfilling of the basic multicellular unit.

      Although zoledronic acid and denosumab are currently regarded as the most potent
      antiresorptive agents, there is no head-to-head comparative study. This study primarily aims
      to the comparative effect of zoledronic acid and denosumab on serum sclerostin levels and
      secondarily on serum dickkopf-1, osteoprotegerin, RANKL and bone turnover markers
      (procollagen type I N-terminal peptide [PINP] and C-terminal cross-linking telopeptide of
      type I collagen [CTX]).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sclerostin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Serum sclerostin levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dickkopf-1</measure>
    <time_frame>12 weeks</time_frame>
    <description>Serum dickkopf-1 (DKK-1) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OPG/RANKL</measure>
    <time_frame>12 weeks</time_frame>
    <description>Serum osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcium metabolism</measure>
    <time_frame>12 weeks</time_frame>
    <description>Serum calcium, phosphate, intact parathyroid hormone (PTH) and 25-hydroxy-vitamin D (25OHD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone turnover</measure>
    <time_frame>12 weeks</time_frame>
    <description>Serum bone turnover markers (total alkaline phosphatase [TSAP], type I N-terminal peptides [PINP] και C-terminal cross-linking telopeptide of type I collagen [CTX])</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Zoledronic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>Denosumab (injection), 60 mg, administered as a single subcutaneous injection once</description>
    <arm_group_label>Denosumab</arm_group_label>
    <other_name>Prolia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>Zoledronic acid (vial), 5 mg, administered once as a single 15- to 30-minute intravenous infusion</description>
    <arm_group_label>Zoledronic Acid</arm_group_label>
    <other_name>Aclasta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian postmenopausal women older than 40 years

          -  Low bone mass at lumbar spine (L2-L4) or femoral neck (BMD T-score of ≤ -2.0) or BMD
             T-score of &gt; -2.0 coexistent with low-energy fracture of vertebral, femoral neck or
             forearm

          -  Patient's informed consent to participate

        Exclusion Criteria:

          -  Secondary osteoporosis

          -  Any bone and mineral disorder other than osteoporosis, including primary or secondary
             hyperparathyroidism, Paget's disease of bone, osteogenesis imperfecta, rheumatologic
             diseases, paraplegia, chronic immobilization

          -  Severe liver or kidney disease (creatinine clearance &lt; 60ml/min/1.73m2) or liver or
             kidney transplantation

          -  Premature ovarian failure

          -  Uncontrolled thyroid disease

          -  Any malignancy

          -  Any musculoskeletal injury or surgical procedure 6 months prior to baseline

          -  Dental surgery or teeth removed 3 months prior to baseline or plan to

          -  History or concomitant medications that could affect bone metabolism, including
             immunosuppressive, anticonvulsant, antiviral and anti-tuberculosis agents, addictive
             drugs, corticosteroids, non-steroidal anti-inflammatory drugs, amiodarone,
             thiazolidinediones, interferon, metronidazole, and tamoxifen
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stergios A Polyzos, MD, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aristotle University Of Thessaloniki</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Athanasios D Anastasilakis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>424 General Military Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Polyzois Makras, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>251 Hellenic Air Force &amp; VA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>251 Hellenic Air Force Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attikis</state>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>424 General Military Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Anastasilakis AD, Polyzos SA, Makras P, Sakellariou GT, Bisbinas I, Gkiomisi A, Delaroudis S, Gerou S, Ballaouri I, Oikonomou D, Papapoulos SE. Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass. Bone. 2012 May;50(5):1130-4. doi: 10.1016/j.bone.2012.02.006. Epub 2012 Feb 15.</citation>
    <PMID>22366634</PMID>
  </reference>
  <reference>
    <citation>Anastasilakis AD, Polyzos SA, Anastasilakis CD, Toulis KA, Makras P. Denosumab and bisphosphonates: rivals or potential &quot;partners&quot;? A &quot;hybrid&quot; molecule hypothesis. Med Hypotheses. 2011 Jul;77(1):109-11. doi: 10.1016/j.mehy.2011.03.039. Epub 2011 Apr 8.</citation>
    <PMID>21482033</PMID>
  </reference>
  <reference>
    <citation>Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide. Osteoporos Int. 2012 Mar;23(3):1171-6. doi: 10.1007/s00198-010-1525-6. Epub 2011 Jan 11.</citation>
    <PMID>21305266</PMID>
  </reference>
  <reference>
    <citation>Anastasilakis AD, Toulis KA, Polyzos SA, Terpos E. RANKL inhibition for the management of patients with benign metabolic bone disorders. Expert Opin Investig Drugs. 2009 Aug;18(8):1085-102. doi: 10.1517/13543780903048929. Review.</citation>
    <PMID>19558335</PMID>
  </reference>
  <reference>
    <citation>Anastasilakis AD, Toulis KA, Goulis DG, Polyzos SA, Delaroudis S, Giomisi A, Terpos E. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res. 2009 Oct;41(10):721-9. doi: 10.1055/s-0029-1224109. Epub 2009 Jun 17. Review.</citation>
    <PMID>19536731</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2012</study_first_submitted>
  <study_first_submitted_qc>April 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <last_update_submitted>January 15, 2013</last_update_submitted>
  <last_update_submitted_qc>January 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Stergios A. Polyzos, MD, MSc, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>bone turnover</keyword>
  <keyword>denosumab</keyword>
  <keyword>postmenopausal osteoporosis</keyword>
  <keyword>sclerostin</keyword>
  <keyword>zolendronic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

